SpringerLink
Log in

CD163-positive cancer cells are potentially associated with high malignant potential in clear cell renal cell carcinoma

  • Original Paper
  • Published:
Medical Molecular Morphology Aims and scope Submit manuscript

Abstract

CD163 is preferentially expressed by monocyte/macrophages; however, recent studies using immunohistochemistry (IHC) have reported that some cancer cells also express CD163. In the present IHC study, we investigated CD163 staining of cancer cells and macrophages in clear cell renal cell carcinoma (ccRCC) tissues and determined the relationship between cancer cell CD163 expression and clinical prognosis in patients with ccRCC. IHC for CD163 was performed in ccRCC tissues from 103 patients. CD163-positive cancer cells were detected in 35% of the patients (36/103); however, the positive signals on cancer cells were significantly lower than those on macrophages. CD163-positive cancer cells were preferentially detected in patients with high T classification, and females, and were significantly associated with shortened progression-free survival and a lower overall survival ratio. Notably, a high intensity of CD163-positive macrophage infiltration was detected in the CD163-positive cancer cell-high tumor areas. Although CD163 mRNA was detected in cultured macrophages, no CD163 mRNA was detected in two cultured RCC cell lines. The detailed mechanism by which a positive signal is detected on cancer cells has not been clarified. Detection of the CD163 antigen on cancer cells might be a useful marker for evaluating the clinical course of patients with ccRCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Motzer RJ, Bukowski RM (2006) Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24:5601–5608

    Article  CAS  PubMed  Google Scholar 

  2. Tanigawa G, Kawashima A, Yamaguchi S, Nishimura K, Miyoshi S, Kajikawa J, Meguro N, Yosioka T, Oka T, Hara T, Takayama H, Nonomura N, Osaka Renal Cell Carcinoma Clinical Study Collaboration (2011) Clinical outcome and prognostic factors of sorafenib in Japanese patients with advanced renal cell carcinoma in general clinical practice. Jpn J Clin Oncol 41:1265–1270

    Article  PubMed  Google Scholar 

  3. Mikami S, Oya M, Mizuno R, Kosaka T, Ishida M, Kuroda N, Nagashima Y, Katsube K, Okada Y (2016) Recent advances in renal cell carcinoma from a pathological point of view. Pathol Int 66:481–490

    Article  CAS  PubMed  Google Scholar 

  4. Nagashima Y, Kuroda N, Yao M (2013) Transition of organizational category on renal cancer. Jpn J Clin Oncol 43:233–242

    Article  PubMed  Google Scholar 

  5. Fabriek BO, van Bruggen R, Deng DM, Ligtenberg AJ, Nazmi K, Schornagel K, Vloet RP, Dijkstra CD, van den Berg TK (2009) The macrophage scavenger receptor CD163 functions as an innate immune sensor for bacteria. Blood 113:887–892

    Article  CAS  PubMed  Google Scholar 

  6. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, Moestrup SK (2001) Identification of the haemoglobin scavenger receptor. Nature 409:198–201

    Article  CAS  PubMed  Google Scholar 

  7. Komohara Y, Ohnishi K, Kuratsu J, Takeya M (2008) Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol 216:15–24

    Article  CAS  PubMed  Google Scholar 

  8. Takeya M, Komohara Y (2016) Role of tumor-associated macrophages in human malignancies: friend or foe? Pathol Int 66:491–505

    Article  PubMed  Google Scholar 

  9. Komohara Y, **ushi M, Takeya M (2014) Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci 105:1–8

    Article  CAS  PubMed  Google Scholar 

  10. Shabo I, Stål O, Olsson H, Doré S, Svanvik J (2008) Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival. Int J Cancer 123:780–786

    Article  CAS  PubMed  Google Scholar 

  11. Maniecki MB, Etzerodt A, Ulhøi BP, Steiniche T, Borre M, Dyrskjøt L, Orntoft TF, Moestrup SK, Møller HJ (2012) Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells. Int J Cancer 131:2320–2331

    Article  CAS  PubMed  Google Scholar 

  12. Shabo I, Svanvik J (2011) Expression of macrophage antigens by tumor cells. Adv Exp Med Biol 714:141–150

    Article  CAS  PubMed  Google Scholar 

  13. Kanno H, Nishihara H, Wang L, Yuzawa S, Kobayashi H, Tsuda M, Kimura T, Tanino M, Terasaka S, Tanaka S (2013) Expression of CD163 prevents apoptosis through the production of granulocyte colony-stimulating factor in meningioma. Neuro Oncol 15:853–864

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Shabo I, Midtbö K, Andersson H, Åkerlund E, Olsson H, Wegman P, Gunnarsson C, Lindström A (2015) Macrophage traits in cancer cells are induced by macrophage-cancer cell fusion and cannot be explained by cellular interaction. BMC Cancer 15:922

    Article  PubMed  PubMed Central  Google Scholar 

  15. Shabo I, Olsson H, Elkarim R, Sun XF, Svanvik J (2014) Macrophage infiltration in tumor stroma is related to tumor cell expression of CD163 in colorectal cancer. Cancer Microenviron 7:61–69

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Kitada S, Yamada S, Kuma A, Ouchi S, Tasaki T, Nabeshima A, Noguchi H, Wang KY, Shimajiri S, Nakano R, Izumi H, Kohno K, Matsumoto T, Sasaguri Y (2013) Polypeptide N-acetylgalactosaminyl transferase 3 independently predicts high-grade tumours and poor prognosis in patients with renal cell carcinomas. Br J Cancer 109:472–481

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Ma C, Komohara Y, Ohnishi K, Shimoji T, Kuwahara N, Sakumura Y, Matsuishi K, Fujiwara Y, Motoshima T, Takahashi W, Yamada S, Kitada S, Fujimoto N, Nakayama T, Eto M, Takeya M (2016) Infiltration of tumor-associated macrophages is involved in CD44 expression in clear cell renal cell carcinoma. Cancer Sci 107:700–707

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Nakagawa T, Ohnishi K, Kosaki Y, Saito Y, Horlad H, Fujiwara Y, Takeya M, Komohara Y (2017) Optimum immunohistochemical procedures for analysis of macrophages in human and mouse formalin fixed paraffin-embedded tissue samples. J Clin Exp Hematop (in press)

  19. Horlad H, Ma C, Yano H, Pan C, Ohnishi K, Fujiwara Y, Endo S, Kikukawa Y, Okuno Y, Matsuoka M, Takeya M, Komohara Y (2016) An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma. Cancer Sci 107:1696–1704

    Article  PubMed  PubMed Central  Google Scholar 

  20. Komohara Y, Hasita H, Ohnishi K, Fujiwara Y, Suzu S, Eto M, Takeya M (2011) Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci 102:1424–1431

    Article  CAS  PubMed  Google Scholar 

  21. Komohara Y, Fujiwara Y, Ohnishi K, Takeya M (2016) Tumor-associated macrophages: potential therapeutic targets for anti-cancer therapy. Adv Drug Deliv Rev 99:180–185

    Article  CAS  PubMed  Google Scholar 

  22. Hasita H, Komohara Y, Okabe H, Masuda T, Ohnishi K, Lei XF, Beppu T, Baba H, Takeya M (2010) Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci 101:1913–1919

    Article  CAS  PubMed  Google Scholar 

  23. Chen EH, Olson EN (2005) Unveiling the mechanisms of cell-cell fusion. Science 308:369–373

    Article  CAS  PubMed  Google Scholar 

  24. Ding J, ** W, Chen C, Shao Z, Wu J (2012) Tumor associated macrophage × cancer cell hybrids may acquire cancer stem cell properties in breast cancer. PLoS One 7:e41942

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Hintz KA, Rassias AJ, Wardwell K, Moss ML, Morganelli PM, Pioli PA, Givan AL, Wallace PK, Yeager MP, Guyre PM (2002) Endotoxin induces rapid metalloproteinase-mediated shedding followed by up-regulation of the monocyte hemoglobin scavenger receptor CD163. J Leukoc Biol 72:711–717

    CAS  PubMed  Google Scholar 

  26. Matsushita N, Kashiwagi M, Wait R, Nagayoshi R, Nakamura M, Matsuda T, Hogger P, Guyre PM, Nagase H, Matsuyama T (2002) Elevated levels of soluble CD163 in sera and fluids from rheumatoid arthritis patients and inhibition of the shedding of CD163 by TIMP-3. Clin Exp Immunol 130:156–161

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Weiss M, Schneider EM (2006) Soluble CD163: an age-dependent, anti-inflammatory biomarker predicting outcome in sepsis. Crit Care Med 34:2682–2683

    Article  PubMed  Google Scholar 

  28. Møller HJ, Moestrup SK, Weis N, Wejse C, Nielsen H, Pedersen SS, Attermann J, Nexø E, Kronborg G (2006) Macrophage serum markers in pneumococcal bacteremia: prediction of survival by soluble CD163. Crit Care Med 34:2561–2566

    Article  PubMed  Google Scholar 

  29. Reid M, Ma Y, Scherzer R, Price JC, French AL, Plankey MW, Grunfeld C, Tien PC (2017) Higher CD163 levels are associated with insulin resistance in hepatitis C virus-infected and HIV-infected adults. AIDS 31:385–393

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Hassan WA, Baraka EA, Elnady BM, Gouda TM, Fouad N (2016) Serum Soluble CD163 and its association with various disease parameters in patients with systemic sclerosis. Eur J Rheumatol 3:95–100

    Article  PubMed  PubMed Central  Google Scholar 

  31. Enomoto Y, Suzuki Y, Hozumi H, Mori K, Kono M, Karayama M, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Suzuki D, Ogawa N, Nakashima R, Mimori T, Iwashita T, Suda T (2017) Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease. Arthritis Res Ther 19:9

    Article  PubMed  PubMed Central  Google Scholar 

  32. Nederby L, Roug AS, Knudsen SS, Skovbo A, Kjeldsen E, Moller HJ, Hokland M (2015) Soluble CD163 as a prognostic biomarker in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 56:3219–3221

    Article  PubMed  Google Scholar 

  33. Andersen MN, Abildgaard N, Maniecki MB, Møller HJ, Andersen NF (2014) Monocyte/macrophage-derived soluble CD163: a novel biomarker in multiple myeloma. Eur J Haematol 93:41–47

    Article  CAS  PubMed  Google Scholar 

  34. No JH, Moon JM, Kim K, Kim YB (2013) Prognostic significance of serum soluble CD163 level in patients with epithelial ovarian cancer. Gynecol Obstet Invest 75:263–267

    Article  CAS  PubMed  Google Scholar 

  35. Sugaya M, Miyagaki T, Ohmatsu H, Suga H, Kai H, Kamata M, Fujita H, Asano Y, Tada Y, Kadono T, Okochi H, Sato S (2012) Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma. J Dermatol Sci 68:45–51

    Article  CAS  PubMed  Google Scholar 

  36. Jensen TO, Schmidt H, Møller HJ, Høyer M, Maniecki MB, Sjoegren P, Christensen IJ, Steiniche T (2009) Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol 27:3330–3337

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Ms. Ikuko Miyakawa, and Ms. Yui Hayashida for their technical assistance. This work was supported by Grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (KAKENHI, No. 16H05162, 16K11013).

Author information

Author notes

  1. Chaoya Ma and Hasita Horlad equally contributed to this work.

Authors and Affiliations

  1. Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Honjo 1-1-1, Kumamoto, 860-8556, Japan

    Chaoya Ma, Hasita Horlad, Koji Ohnishi, Takenobu Nakagawa, Motohiro Takeya & Yoshihiro Komohara

  2. Department of Pathology, University of Occupational and Environmental Health, Kitakyusyu, Japan

    Sohsuke Yamada & Toshiyuki Nakayama

  3. Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyusyu, Japan

    Shohei Kitada & Naohiro Fujimoto

  4. Department of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

    Takanobu Motoshima & Tomomi Kamba

Authors
  1. Chaoya Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hasita Horlad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Koji Ohnishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takenobu Nakagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sohsuke Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shohei Kitada
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Takanobu Motoshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tomomi Kamba
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Toshiyuki Nakayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Naohiro Fujimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Motohiro Takeya
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yoshihiro Komohara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshihiro Komohara.

Ethics declarations

Conflict of interest

The authors have no financial competing interests to declare.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ma, C., Horlad, H., Ohnishi, K. et al. CD163-positive cancer cells are potentially associated with high malignant potential in clear cell renal cell carcinoma. Med Mol Morphol 51, 13–20 (2018). https://doi.org/10.1007/s00795-017-0165-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00795-017-0165-8

Keywords

Search

Navigation